Wei, S. , Tung, C. et al. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553.
- info@buhlmannlabs.ch
- +41 61 487 12 12
IBDoc®
BÜHLMANN IBDoc®: Walsh, A, Kormilitzin, A. et al. New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC). 13th Congress of ECCO 2018, Feb 14 – 17, 2018. Vienna, Austria. Highlights from this Poster “Conclusions. An FCal <180 g/g is indicative of endoscopic and histological remission. FCal
Read more
BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®. CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Read more
BÜHLMANN fCAL® turbo and IBDoc®: Hejla, J, Theedeb, K, et al. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Practical Laboratory Medicine; 10 (2018) 10-14. PMID: 29234707 DOI: 10.1016/j.plabm.2017.11.002 Highlights from this Publication “This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients. Point of care
Read more
Social Links